A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).

开始日期2021-08-17

申办/合作机构

Alkahest, Inc.初创企业

EUCTR2019-001059-37-BG / Not yet recruiting临床2期

Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid

开始日期2020-12-22

申办/合作机构

Alkahest, Inc.初创企业

NCT04499235 / Terminated临床2期

Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid

This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).

开始日期2020-01-30

申办/合作机构

Alkahest, Inc.初创企业

100 项与 Lazucirnon 相关的临床结果

登录后查看更多信息

100 项与 Lazucirnon 相关的转化医学

登录后查看更多信息

100 项与 Lazucirnon 相关的专利（医药）

登录后查看更多信息

项与 Lazucirnon 相关的文献（医药）

2024-03-01·American Journal of Clinical Dermatology

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Review

作者: Eyerich, Kilian ; Patsatsi, Aikaterini ; Karakioulaki, Meropi

ABASTRACTBullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.

2022-06-01·Retina2区 · 医学

SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

2区 · 医学

Article

作者: Newman, Erin M ; Sikorski, Bartosz L ; Jeffords, Elizabeth ; Jackson, Sam ; Stewart, Michael W ; Konopińska, Joanna ; Rawner, Esther S ; Garg, Seema

Purpose:To evaluate the safety and therapeutic effects of orally administered AKST4290 (formerly BI 144807 and ALK4290) in treatment-naive patients with neovascular age-related macular degeneration.Methods:In this prospective, multicenter, open-label Phase 2a pilot clinical study, 30 patients with newly diagnosed neovascular age-related macular degeneration self-administered AKST4290 (400 mg) orally twice daily for 6 weeks. Patients were examined weekly for safety, to measure best-corrected visual acuity (BCVA), and to perform exploratory morphologic assessments. The primary endpoint was the mean change in BCVA from baseline to end of treatment, and the secondary endpoint was safety. Exploratory endpoints investigated potential changes in macular morphology.Results:Mean BCVA improved by +7.0 letters (95% CI, 2.2–11.7); 24 patients (82.8%) had stable or improved BCVA, with 6 (20.7%) gaining ≥15 letters. No patients experienced severe or serious adverse events.Conclusion:In this 6-week study, AKST4290 treatment was associated with improved BCVA scores in patients with treatment-naive neovascular age-related macular degeneration. All adverse events were mild or moderate in severity and no safety issues were identified. Treatment of neovascular age-related macular degeneration with AKST4290 warrants further investigation in randomized, placebo-controlled trials.

2020-05-01·Asia-Pacific Journal of Ophthalmology4区 · 医学

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

4区 · 医学

ReviewOA

作者: Chhablani, Jay ; Khanani, Arshad M ; Singh, Sumit Randhir ; Jhingan, Mahima ; Aziz, Aamir A ; Samanta, Anindya

AbstractAge-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily 2 types—neovascular AMD (nAMD) with the presence of choroid neovascularization and nonneovascular AMD (nnAMD) with geographic atrophy. Although there are 4 anti-vascular endothelial growth factor drugs either widely used or approved for the former, there are no current treatments for the latter. This review will highlight upcoming treatments for AMD currently in clinical trials. For nAMD: Abicipar pegol, an intravitreal anti-vascular endothelial growth factor based on designed ankyrin repeat proteins (DARPins) is currently pending approval. Conbercept and Faricimab, 2 intravitreal anti-growth factors, are currently in phase 3. Nine other upcoming agents have at least produced results in the 1B/2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.

项与 Lazucirnon 相关的新闻（医药）

2023-04-20

·PRNewswire

Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight

Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important dopamine chemical. Studies have shown that symptoms of Parkinson's develop in patients with an 80% or greater loss of dopamine-producing cells in the substantia nigra. Most Parkinson's patients are treated with medications to relieve the symptoms of the disease. These medications work by stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or by inhibiting some of the acetylcholine that is produced (anticholinergic medications), therefore restoring the balance between the chemicals in the brain. LAS VEGAS, April 19, 2023 /PRNewswire/ -- DelveInsight's ' Parkinson's Disease Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline Parkinson's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Parkinson's disease pipeline domain. Key Takeaways from the Parkinson's Disease Pipeline Report DelveInsight's Parkinson's disease pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies for Parkinson's disease treatment. Key Parkinson's disease companies such as Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others are evaluating new Parkinson's disease drugs to improve the treatment landscape. Promising Parkinson's disease pipeline therapies in various stages of development include Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, Aadipose-Derived Mesenchymal Stem Cells, ND0612, P2B001, 1ST-103, 1ST-105, and others. In January 2023, Neurocrine Biosciences and Voyager Therapeutics announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases. The collaboration includes Voyager's preclinical, intravenously administered GBA1 gene therapy program for Parkinson's and other GBA1-mediated diseases, combining a GBA1 gene replacement payload with novel capsids from Voyager's TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform. In addition, Neurocrine Biosciences and Voyager have agreed to collaborate on three new gene therapy programs directed to rare CNS targets, each also leveraging Voyager's novel TRACER capsids. In October 2022, Biogen Inc. and Denali Therapeutics Inc. announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 (DNL151), as compared to placebo in approximately 400 participants with Parkinson's disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene. In September 2022, Neuron23, Inc. an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. Request a sample and discover the recent advances in Parkinson's disease drug treatment @ Parkinson's Disease Pipeline Report The Parkinson's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Parkinson's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Parkinson's disease clinical trial landscape. Parkinson's Disease Overview Parkinson's disease is a progressive disorder caused by nerve cell degeneration in the substantia nigra, a part of the brain that controls movement. These nerve cells die or become impaired, losing the ability to produce dopamine, an important chemical. According to research, symptoms of Parkinson's disease develop in patients who have an 80% or greater loss of dopamine-producing cells in the substantia nigra. Dopamine works typically in tandem with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in the movement. This balance is disrupted when there is insufficient dopamine, resulting in tremors (trembling in the hands, arms, legs, and jaw), rigidity (stiffness of the limbs), slowness of movement, and impaired balance and coordination - the hallmark Parkinson's disease symptoms. The cause of Parkinson's disease is largely unknown. However, as potential causes of the disease, theories involving oxidative damage, environmental toxins, genetic factors, and accelerated aging have been discussed. The majority of Parkinson's patients are given medications to alleviate their symptoms. These Parkinson's disease medications work by either stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or inhibiting some of the acetylcholine produced (anticholinergic medications), restoring the balance of chemicals in the brain. Find out more about drugs for Parkinson's disease @ New Parkinson's Disease Drugs A snapshot of the Parkinson's Disease Pipeline Drugs mentioned in the report: Learn more about the emerging Parkinson's disease pipeline therapies @ Parkinson's Disease Clinical Trials Parkinson's Disease Therapeutics Assessment The Parkinson's disease pipeline report proffers an integral view of Parkinson's disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Parkinson's Disease Pipeline Report Coverage: Global Parkinson's Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Parkinson's Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Parkinson's Disease Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous Parkinson's Disease Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine Parkinson's Disease Therapeutics Assessment By Mechanism of Action: Dopamine D1 receptor agonists, Dopamine D5 receptor agonists, Bcr-abl tyrosine kinase inhibitors, Glucagon like peptide 1 receptor agonists, LRRK2 protein inhibitors, Alpha-synuclein inhibitors, Dopamine receptor agonists Key Parkinson's Disease Companies: Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others. Key Parkinson's Disease Pipeline Therapies: Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, Aadipose-Derived Mesenchymal Stem Cells, ND0612, P2B001, and others. Dive deep into rich insights for new drugs for Parkinson's disease treatment; visit @ Parkinson's Disease Medications Table of Contents For further information on the Parkinson's disease pipeline therapeutics, reach out @ Parkinson's Disease Drug Treatment Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, among others. Parkinson's Disease Epidemiology Forecast Parkinson's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Parkinson's disease epidemiology trends. Dementia with Lewy Bodies Pipeline Dementia with Lewy Bodies Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dementia with Lewy bodies companies, including Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others. Dementia with Lewy Bodies Epidemiology Forecast Dementia with Lewy Bodies Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted dementia with Lewy bodies epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Dementia Market Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies, including Hoffmann-La Roche, Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis, among others. Parkinson's Disease-Related Dementia Market Parkinson's Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床3期

2022-06-13

·PRNewswire

The Age-related macular degeneration market growth is expected to boost owing to the expected launch of therapies, increasing prevalence of Age-related macular degeneration, development in the field of gene therapy, patient-friendly dosage regimes, and several other factors during the forecast period. LAS VEGAS, June 13, 2022 /PRNewswire/ -- DelveInsight's Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, Age-related macular degeneration emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key Takeaways from the Age-related Macular Degeneration Market Report As per DelveInsight analysis, the Age-related macular degeneration market size in the 7MM was approximately USD 9.8 billion in 2021. As per DelveInsight estimation, the Dry AMD market size was approximately USD 1,377 million, and the Wet AMD market size was approximately USD 8,463 million, which is further expected to increase by 2032. As per the estimates, the total Age-related macular degeneration prevalent cases in the 7MM was approximately 51.7 million in 2021. Leading Age-related macular degeneration companies Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others are developing novel Age-related Macular Degeneration drugs which can be available in the Age-related Macular Degeneration market in the upcoming years. The Wet Age-related macular degeneration therapies in the pipeline include OPT-302, KSI-301, RGX-314, AKST4290, GB-102 (Sunitinib Malate), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), and others. The Dry Age-related Macular Degeneration therapies in the pipeline include Danicopan (ALXN2040), EG-301, RG6147 (RO7171009), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others. The expected launch of therapies and the increasing prevalence will lead to Age-related macular degeneration market growth during the forecast period. Discover more about therapies set to grab major age-related macular Degeneration market share @ Age-related Macular Degeneration Market Landscape Age-related Macular Degeneration Overview Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries around the world, with a significant impact on the quality of life of the affected people. With the current expensive standard of care, the increase in Age-related macular degeneration life expectancy brings an increase in the number of reported cases, putting major stress on health care systems. Age-related macular degeneration (AMD) can also be characterized as either dry Age-related macular degeneration (atrophic or non-neovascular) or wet Age-related macular degeneration (exudative or neovascular). The most common Age-related macular degeneration symptoms include blurry or fuzzy vision, loss of central vision, difficulty in recognizing familiar faces, and others. Visual acuity test, pupil dilation, fluorescein angiography, Amsler grid, and others are the following tests used for Age-related macular degeneration diagnosis. Age-related Macular Degeneration Epidemiology Segmentation As per DelveInsight, there were approx 51.7 million Age-related macular degeneration prevalent cases in the 7MM in 2021. Among the total diagnosed cases of Age-related macular degeneration, the highest cases were observed for dry Age-related macular degeneration in 2021. The Age-related macular degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases of Age-related Macular Degeneration Total Diagnosed Prevalent Cases of Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases of AMD Total Age-specific Cases of Wet AMD, and Dry AMD Total Diagnosed Dry AMD Cases by Stages Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment Download the report to understand which factors are driving Age-related macular degeneration epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights Wet Age-related Macular Degeneration Treatment Market Photodynamic therapy, which employed an intravenous drug (injected into a vein) and laser to seal off bleeding blood vessels, was the best available Age-related macular degeneration treatment fifteen years ago. However, improvements in medical research have revealed VEGF as a critical pathophysiological factor in the development of neovascular AMD, with an important involvement in angiogenesis, vascular permeability, and inflammatory response. Anti-VEGF intravitreal injections have provided a new therapeutic window in the wet AMD treatment, effectively stopping the pathophysiological process of AMD and restoring retinal shape and function. Anti-VEGF therapies such as ranibizumab, aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo) are intravitreal injections given for wet AMD treatment. Though existing anti-VEGF therapies have transformed the way wet AMD is treated and greatly improved the lives of many patients, they will face stiff competition from new biosimilars and off-label drugs when their patents expire in the coming years. Furthermore, current anti-VEGF therapies have several unmet needs. Dry Age-related Macular Degeneration Treatment Market Currently, there is no approved dry AMD treatment, and there is a significant unmet need for a therapy to decrease its progression. Dry AMD's pathogenesis is poorly known. On the other hand, failure to achieve the primary outcomes may be due to the advanced stage of the disease rather than a lack of action on appropriate targets. Several pharmaceutical companies are currently working on developing novel therapies for dry AMD treatment. The therapies in the dry AMD pipeline include Pegcetacoplan (Apellis Pharmaceuticals), Zimura (Iveric bio), RO7171009; RG6147 (Genentech), IONIS-FB-LRx (Ionis Pharmaceuticals/ Roche), Luminate (Allegro Ophthalmics), NGM621 (NGM Biopharmaceuticals), Elamipretide (Stealth BioTherapeutics), CPCB-RPE1 (Regenerative Patch Technologies), OpRegen (CellCure Neurosciences/Lineage Cell Therapeutics/ Roche), GT005 (Gyroscope Therapeutics), and others. These therapies come with different types of mechanisms of action, including C3 inhibitor, C5 inhibitor, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitor, HtrA1, ASO Complement Factor B, and others. Two C3 inhibitors, NGM621 (NGM Biopharmaceuticals) and pegcetacoplan (Apellis Pharmaceuticals), and one C5 inhibitor, Zimura (Iveric Bio), are showing promise as prospective treatments to slow the course of geographic atrophy. To know more about Age-related macular degeneration treatment visit @ Age-related Macular Degeneration Treatment Guidelines Wet Age-related Macular Degeneration Pipeline Therapies and Key Companies OPT-302: Opthea Limited KSI-301: Kodiak Sciences Inc. RGX-314: REGENXBIO AKST4290: Alkahest Inc GB-102 (Sunitinib Malate): Graybug Vision RBM-007: Ribomic USA Inc Lytenava (Bevacizumab-vikg): Outlook Therapeutics, Inc. UBX1325: Unity Biotechnology, Inc PAN-90806: PanOptica, Inc. CLS-AX (Axitinib): Clearside Biomedical Others Dry Age-related Macular Degeneration Pipeline Therapies and Key Companies Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca EG-301: Evergreen Therapeutics RG6147 (RO7171009): Roche (Genentech) ALK-001: Alkeus Pharmaceuticals Elamipretide: Stealth BioTherapeutics OpRegen: CellCure Neurosciences CPCB-RPE1: Regenerative Patch Technologies Luminate (Risuteganib): Allegro Ophthalmics ANX007: Annexon Biosciences NGM621: NGM Biopharmaceuticals LNP023 (Iptacopan): Novartis IONIS-FB-LRx: Ionis Pharmaceuticals Pegcetacoplan: Apellis Pharmaceuticals Zimura (Avacincaptad Pegol): Iveric Bio GT005: Gyroscope Therapeutics and Novartis RPESC-RPE-4W: Luxa Biotechnology GEM103: Gemini Therapeutics Others Learn more about the dry AMD treatments in clinical trials @ New Treatment for Dry AMD Wet Age-related Macular Degeneration Market Dynamics The rising prevalence of wet AMD and the growing geriatric population are two significant factors driving the growth of the wet AMD market. Moreover, the wet AMD market dynamics are changing as extensive research and development have helped understand the histopathology and pathophysiology of wet AMD. Development in the field of gene therapy and a robust pipeline are also propelling the wet AMD market growth. However, some factors restrain the growth of the wet AMD market. Patients do not contact a physician until they have intermediate to severe AMD symptoms, making timely diagnosis extremely difficult. Moreover, the high cost of therapy, with gene therapy costing over USD 400,000, presents a significant barrier to treatment availability. In addition, the competitive treatment landscape and emerging biosimilars may also limit the growth of the wet AMD market. Dry Age-related Macular Degeneration Market Dynamics The dry AMD market is still untapped. The enormous and growing patient pool with no approved or adequate therapies provides companies with attractive prospects; the estimated potential is similar to wet AMD. Moreover, the dry AMD pipeline includes peptide derivatives, antibodies, antisense oligonucleotides, stem cell treatment, and gene therapy that function on various mechanisms such as C1q, C3, and C5 inhibitors, cell replacements, HtrA Serine Peptidase 1 inhibitor, and others. The launch of these therapies will boost the dry AMD market growth. Furthermore, the increasing prevalence of dry AMD is also driving the dry AMD market forward. However, limited knowledge of pathophysiology, disease severity, and consequences affect the development of efficacious treatment for dry AMD. Moreover, emerging gene therapies and stem cell therapies for dry AMD may face hurdles in access and reimbursement due to their anticipated high cost and will restrain the growth of the dry AMD market. Scope of the Age-related Macular Degeneration Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Age-related Macular Degeneration Companies: Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others Key Wet Age-related Macular Degeneration Therapies: OPT-302, KSI-301, RGX-314, AKST4290, GB-102 (Sunitinib Malate), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), and others Key Dry Age-related Macular Degeneration Therapies: Danicopan (ALXN2040), EG-301, RG6147 (RO7171009), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others Therapeutic Assessment: Age-related Macular Degeneration current marketed and emerging therapies Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement Discover more about Age-related macular degeneration drugs in development @ Age-related Macular Degeneration Clinical Trials Table of Contents Get in touch with our Business executive @ Healthcare Due Diligence Services Related Reports Age-related Macular Degeneration Epidemiology Age-related Macular Degeneration Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Age-related Macular Degeneration epidemiology in the 7MM. Age-related Macular Degeneration Pipeline Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Age-related Macular Degeneration companies including Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc. , among others. Wet Age-related Macular Degeneration Market Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wet Age-related Macular Degeneration companies including Alkahest Inc, Graybug Vision, Clearside Biomedical, among others. Dry Age-related Macular Degeneration Market Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Dry Age-related Macular Degeneration companies including Alkeus Pharmaceuticals, Dobecure, Iveric Bio, among others. Wet Age-related Macular Degeneration Pipeline Wet Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wet Age-related Macular Degeneration companies including Opthea Limited, Kodiak Sciences Inc., REGENXBIO, among others. Dry Age-related Macular Degeneration Pipeline Dry Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dry Age-related Macular Degeneration companies including Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, among others. Other Trending Reports Periodontal Disease Market | Open-Angle Glaucoma Market | Obsessive-Compulsive Disorder Market | Nicotine Addiction Market | Nephrosclerosis Market | Muscle Invasive Bladder cancer Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market Related Healthcare Blogs Dry AMD Market: Pegcetacoplan vs Zimura Wet Age-related Macular Degeneration Market Outlook Eye Disorders Treatment Market About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

基因疗法抗体生物类似药寡核苷酸细胞疗法

2021-03-09

·GlobeNewswire

Los Angeles, USA , March 09, 2021 (GLOBE NEWSWIRE) -- Age-related Macular Degeneration Pipeline Analysis of 70+ Key Companies and 70+ Key Therapeutic Products DelveInsight anticipates the launch of ABP 938, KSI-301, OPT-302, and RGX-314 in the Age-related Macular Degeneration Pipeline as the most promising therapies. DelveInsight’s Age-related Macular Degeneration (AMD) Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the AMD domain. The AMD Pipeline Analysis report offers a 360° view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for Age-related Macular Degeneration emerging therapies. The Age-related Macular Degeneration Pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies. Some of the key takeaways from the Age-related Macular Degeneration Pipeline report: Request for Sample @ Age-related Macular Degeneration Pipeline Insights Age-related Macular Degeneration is a condition that impairs a small central area, macula, located at the center of the retina. It affects a person's central vision due to the formation of distorted, dark spots that gradually progress, thus, affecting the tasks like reading, and diving. Genetic mutations in- and around several complement gene systems, including the CFH gene, contribute to the risk of developing AMD. Further, changes on the long (q) arm of chromosome 10 in a region known as 10q26 are also associated with an increased risk of Age-related Macular Degeneration. Reach out for rich pipeline insights @ Age-related Macular Degeneration Drug Pipeline Age-related Macular Degeneration Drug Profiles KSI 301: Kodiak Sciences KSI 301 is an antibody biopolymer conjugate for the treatment of retinal vascular diseases. It is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Kodiak Sciences is currently evaluating KSI 301 in Phase II/ III trial to evaluate its efficacy and safety versus Aflibercept in patients with Neovascular (Wet) Age-Related Macular Degeneration. Kodiak Sciences initiated a randomized, double-masked, active comparator-controlled, multi-center study (NCT04049266) to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with Neovascular (Wet) Age-related Macular Degeneration. For more information on drug profiles, visit Age-related Macular Degeneration Emerging Therapies Key Age-related Macular Degeneration Pipeline Age-related Macular Degeneration Therapeutic Assessment By Product Type By Stage By Route of Administration By Molecule Type By Mechanism of Action By Targets By Stage and Molecule TypeBy Stage and Route of AdministrationBy Stage and Product Type Dive deeper into Age-related Macular Degeneration Therapeutic Assessment Scope of the Report Coverage: GlobalKey Players: Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq/Formycon, Sinocelltech, RemeGen, Alkahest, Kyowa Kirin, EyePoint Pharmaceutical, IVERIC bio, Kodiak Sciences, Ribomic USA Inc, Sunshine Guojian Pharmaceutical (Shanghai), Lineage Cell Therapeutics, Graybug Vision, Sinocelltech, Luxa Biotechnology, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Samsung Bioepis, Outlook Therapeutics, Unity Biotechnology, Stealth BioTherapeutics, AiViva BioPharma, Ocular Therapeutix, AO GENERIUM, Gyroscope Therapeutics, Ionis Pharmaceuticals, Aerie Pharmaceuticals, Outlook Therapeutics, and several others. Key AMD Pipeline Therapies: Aflibercept biosimilar, Faricimab, ADVM 022, AXT 107, Ranibizumab biosimilar, SCT510A, RC 28 E, ALK4290, KHK4951, EYP-1901, Zimura, RBM-007 Injectable Solution, Drug 601, OpRegen, KSI 301, ABP 938, ADVM-022, SCT510A, GB-102, RPESC-RPE-4W, MA09-hRPE, SCD411, HLX04-O, BAT5906, LY09004, ASP7317 among others. Key Questions Answered Got queries? Reach out to us @ Age-related Macular Degeneration Drug Pipeline Table of Contents Related Reports Age-Related Macular Degeneration MarketDelveInsight's "Age-Related Macular Degeneration - Market Insights, Epidemiology, and Market Forecast-2030" report. Dry Age Macular Degeneration MarketDelveInsight's "Dry Age Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2030" report Wet Age-Related Macular Degeneration MarketDelveInsight's "Wet Age-Related Macular Degeneration (Wet AMD) Market Insights, Epidemiology, and Market Forecast-2030" report. Vernal Keratoconjunctivitis MarketDelveInsight's "Vernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2030" report. Allergic Conjunctivitis MarketDelveInsight's "Allergic Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2030" report Allergic Rhino-Conjunctivitis MarketDelveInsight's "Allergic Rhino-Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2030" report. Anterior Uveitis MarketDelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2030" report. Bacterial Conjunctivitis MarketDelveInsight's "Bacterial Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2030" report. Blepharitis MarketDelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast-2030" report. Central Retinal Vein Occlusion MarketDelveInsight's "Central Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2030" report. Central Serous Chorioretinopathy MarketDelveInsight's "Central Serous Chorioretinopathy Market Insights, Epidemiology, and Market Forecast-2030" report. Choroidal Neovascularization MarketDelveInsight's "Choroidal Neovascularization Market Insights, Epidemiology, and Market Forecast-2030" report. Corneal Endothelial Dystrophy MarketDelveInsight’s ‘Corneal Endothelial Dystrophy (CED) Market Insights, Epidemiology, and Market Forecast—2030’ report. Diabetic Retinopathy MarketDelveInsight’s ‘Diabetic Retinopathy (DR) Market Insights, Epidemiology, and Market Forecast—2030’ report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

抗体生物类似药合作

100 项与 Lazucirnon 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15269

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
大疱性类天疱疮	临床2期	-	Boehringer Ingelheim International GmbH	-
神经变性	临床1期	-	Alkahest, Inc.初创企业	-
糖尿病性视网膜病变	临床前	美国	Alkahest, Inc.初创企业	2021-08-17
帕金森病	临床前	爱沙尼亚	Alkahest, Inc.初创企业	2020-01-16
帕金森病	临床前	美国	Alkahest, Inc.初创企业	2020-01-16
帕金森病	临床前	波兰	Alkahest, Inc.初创企业	2020-01-16
帕金森病	临床前	德国	Alkahest, Inc.初创企业	2020-01-16
帕金森病	临床前	斯洛伐克	Alkahest, Inc.初创企业	2020-01-16
湿性年龄相关性黄斑变性	临床前	匈牙利	Alkahest, Inc.初创企业	2018-04-04
湿性黄斑变性	临床前	匈牙利	Alkahest, Inc.初创企业	2017-01-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05038020 (CTgov)	临床2期	糖尿病性视网膜病变	3	AKST4290 (AKST4290)	醖齋壓夢襯範憲餘窪鹹(積鑰網襯窪觸夢顧觸鬱) = 窪鑰顧壓觸糧簾願製願簾衊艱網鑰獵簾範鹽憲 (鹽願範願糧鏇鹽鹽醖選, 構網齋膚淵觸夢壓選鹹 ~ 簾廠遞夢廠鏇獵艱淵壓) 更多	-	2023-11-01
				Placebo (Placebo)	醖齋壓夢襯範憲餘窪鹹(積鑰網襯窪觸夢顧觸鬱) = 鏇壓鹹觸築廠簾鹹遞壓簾衊艱網鑰獵簾範鹽憲 (鹽願範願糧鏇鹽鹽醖選, 衊網積齋憲憲鑰鏇簾醖 ~ 糧憲廠網夢築廠製願鹽) 更多
NCT04499235 (CTgov)	临床2期	大疱性类天疱疮	6	Mometasone furoate+AKST4290 (Mometasone Furoate + AKST4290)	網獵窪鏇襯觸構鹽鬱範(網製餘顧範範獵積鹽構) = 餘窪顧齋鏇製淵製鏇鑰憲遞簾鑰願襯製糧艱齋 (憲餘網製夢膚願艱選積, 鏇糧範襯鹹壓廠餘製鬱 ~ 膚鬱積膚遞願鏇淵築夢) 更多	-	2023-09-14
				Placebo+Mometasone furoate (Mometasone Furoate + Placebo)	網獵窪鏇襯觸構鹽鬱範(網製餘顧範範獵積鹽構) = 衊願蓋繭膚鑰膚積窪積憲遞簾鑰願襯製糧艱齋 (憲餘網製夢膚願艱選積, 簾顧遞範願選膚鹹鏇糧 ~ 廠淵窪蓋網膚顧衊蓋衊) 更多
NCT04331730 (PHTHALO-205, CTgov)	临床2期	湿性年龄相关性黄斑变性	107	aflibercept+AKST4290 (AKST4290 (800 mg) + Aflibercept)	構糧鹹鏇獵齋廠遞製憲(壓壓簾築鑰築鬱蓋窪夢) = 獵範願構顧鏇遞糧鹹鬱衊鏇齋獵糧繭膚襯鑰遞 (製鹹醖艱壓顧鏇衊鏇鏇, 鏇願襯憲衊簾窪製衊廠 ~ 壓獵願觸鏇鑰網窪積築) 更多	-	2022-10-26
				aflibercept+AKST4290 (AKST4290 (1600 mg) + Aflibercept)	構糧鹹鏇獵齋廠遞製憲(壓壓簾築鑰築鬱蓋窪夢) = 選鹹範蓋鬱襯遞壓壓網衊鏇齋獵糧繭膚襯鑰遞 (製鹹醖艱壓顧鏇衊鏇鏇, 繭簾糧襯餘淵繭襯夢積 ~ 遞憲醖築鹽網糧衊獵醖) 更多
NCT04369430 (TEAL, CTgov)	临床2期	帕金森病	110	AKST4290 (AKST4290)	願淵築鑰蓋鹹齋齋顧蓋(構繭廠鹽蓋遞製築窪餘) = 願齋獵餘積餘鏇遞積構鬱構鹹網選構願觸衊膚 (憲衊艱繭積構膚築範鬱, 艱鏇簾鹽鹹艱襯鑰窪齋 ~ 衊襯蓋夢衊選築艱醖鹹) 更多	-	2022-10-10
				Placebo (Placebo)	願淵築鑰蓋鹹齋齋顧蓋(構繭廠鹽蓋遞製築窪餘) = 窪壓糧積顧網網鏇鏇窪鬱構鹹網選構願觸衊膚 (憲衊艱繭積構膚築範鬱, 憲壓積餘簾構窪鑰積簾 ~ 鑰築餘蓋襯襯憲鹹衊顧) 更多
NCT03558061 (CTgov)	临床2期	湿性年龄相关性黄斑变性	30	ALK4290	獵鹹膚窪鏇餘蓋醖範餘(顧獵遞構夢衊願構繭製) = 觸淵淵鹹窪餘鹽窪憲網齋鏇壓選衊壓淵觸鏇鹽 (築觸鑰窪鏇糧簾夢願觸, 餘簾夢簾鏇蓋網遞憲築 ~ 願憲簾積鬱繭繭鏇憲膚) 更多	-	2020-08-28
NCT03558074 (CTgov)	临床2期	湿性年龄相关性黄斑变性	26	ALK4290	製遞衊願鏇醖觸壓繭醖(糧窪積衊鹽鏇鬱憲鑰構) = 憲顧鏇廠願憲襯簾觸醖艱廠選製鹽壓獵鏇醖鏇 (鏇遞膚淵網鹹醖簾餘膚, 鏇膚網鏇鹹鏇製願獵壓 ~ 鹹醖鑰窪襯淵糧獵積簾) 更多	-	2020-08-28
PO437 (AAO2019)	N/A	湿性年龄相关性黄斑变性 CCR3	-	AKST4290	(築蓋顧窪繭醖膚鑰構構) = 夢淵獵蓋憲蓋鏇窪襯網膚艱遞鏇願壓顧鑰淵壓 (遞積醖鹽壓醖糧簾簾襯 )	积极	2019-10-12
NCT03558074 (GlobeNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	26	AKST-4290	(醖獵網憲遞襯醖鹽積繭) = 鏇艱糧鏇夢鹽願蓋淵繭築蓋製醖艱艱鹽繭膚積 (顧顧襯觸夢醖積網蓋餘 ) 更多	积极	2019-07-29